COMPOSITION FOR THE PREVENTION OR TREATMENT OF TNF-RELATED DISEASES CONTAINING A NEW DERIVATIVE AS AN ACTIVE INGREDIENT AND A METHOD FOR INHIBITING TNF ACTIVITY WITH ITS HELP Russian patent published in 2023 - IPC C07D311/22 A61K31/353 A61K45/06 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to a pharmaceutical composition for the prevention or treatment of diseases associated with increased expression of TNF and selected from a group including rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, Behcet enteritis, ankylosing spondylitis, axial spondyloarthritis, arthritis associated with juvenile enthesitis, osteoarthritis, rheumatic polymyalgia, disseminated sclerosis, systemic lupus erythematosus, asthma, Sjogren’s syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, annular granuloma, Wegener’s granulomatosis, atherosclerosis, vasculitis, heart failure, myocardial infarction, kidney disease, nephritis, graft versus host syndrome, dementia, Alzheimer’s disease, Parkinson’s disease, pain, uveitis, Behcet’s disease, purulent hydradenitis, red flame-shaped pityriasis, lipoid necrobiosis, gangrenous pyoderma, Sweet syndrome, subcortical pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis and septic shock, containing a derivative of 4-benzopyranone, represented by Formula 1, or its pharmacologically acceptable salt as an active ingredient and one or more additives and inhibiting the activity of TNF by direct binding to tumor necrosis factor (TNF): $$$ , in which R¹ is furanyl, thiophenyl or substituted phenyl, represented by the formula $$$ where each of R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently represents hydrogen, chlorine, bromine, fluorine, methyl or methoxy; R² represents hydrogen or the lowest alkyl of (C₁-C₄); and each of R³, R⁴, R⁵ and R⁶ independently represents hydrogen, halogen, methyl or (C₁-C₄)alkoxy, and also refers to the composition of healthy functional nutrition for the prevention or relief of symptoms of diseases associated with increased expression of TNF and to the reagent of the composition for inhibiting TNF activity in vitro.

EFFECT: expansion of the range of solutions for treating TNF-related diseases.

7 cl, 2 tbl, 81 ex, 16 dwg